These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37166677)

  • 21. Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México.
    Casallas-Vanegas A; Gomez-Figueroa E; de Saráchaga AJ; Zabala-Angeles I; García-Estrada C; Salado-Burbano JC; DiazGranados-Palacio MC; Corona-Vázquez T; de Jesús Flores-Rivera J; Rivas-Alonso V
    J Neurol Sci; 2020 Dec; 419():117204. PubMed ID: 33161302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder.
    Shi B; Zhao M; Qiao L; Huang F; Zhou S; Wei Y; Wang J; Wang N
    Mult Scler Relat Disord; 2021 Sep; 54():103143. PubMed ID: 34273608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.
    Huang W; Wang L; Xia J; Li W; Wang M; Yu J; Li Q; Wang B; Pan J; Du L; Ma J; Tan H; Chang X; Lu C; Zhao C; Lu J; Zhou L; ZhangBao J; Quan C;
    Eur J Neurol; 2022 Aug; 29(8):2343-2354. PubMed ID: 35398950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.
    Nosadini M; Alper G; Riney CJ; Benson LA; Mohammad SS; Ramanathan S; Nolan M; Appleton R; Leventer RJ; Deiva K; Brilot F; Gorman MP; Waldman AT; Banwell B; Dale RC
    Neurol Neuroimmunol Neuroinflamm; 2016 Feb; 3(1):e188. PubMed ID: 26819962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic strategies in NMOSD and MOGAD patients: A multicenter cohort study in Latin America.
    Rojas JI; López PA; Criniti J; Pettinicchi JP; Caride A; Correa Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Andrade JSP; Daccach Marques V; Bribiesca Contreras E; Gómez Figueroa E; Flores Rivera J; Galleguillos L; Navas C; Soares Neto HR; Gracia F; Cristiano E; Patrucco L; Becker J; Hamuy F; Alonso R; Man F; Tkachuk V; Nadur D; Lana-Peixoto M; Castillo IS; Carnero Contentti E
    Mult Scler Relat Disord; 2023 Mar; 71():104508. PubMed ID: 36738691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules.
    Trewin BP; Adelstein S; Spies JM; Beadnall HN; Barton J; Ho N; Gallagher KJ; Barnett MH
    Mult Scler Relat Disord; 2020 Aug; 43():102175. PubMed ID: 32417664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    Annovazzi P; Capobianco M; Moiola L; Patti F; Frau J; Uccelli A; Centonze D; Perini P; Tortorella C; Prosperini L; Lus G; Fuiani A; Falcini M; Martinelli V; Comi G; Ghezzi A
    J Neurol; 2016 Sep; 263(9):1727-35. PubMed ID: 27286847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder.
    Lin J; Xue B; Li J; Zhu R; Pan J; Chen Z; Zhang X; Li X; Xia J
    Front Neurol; 2022; 13():891064. PubMed ID: 35599732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders: A 14-Year Real-Life Experience.
    Kim SH; Park NY; Kim KH; Hyun JW; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35853752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
    Du Y; Li C; Hao YF; Zhao C; Yan Q; Yao D; Li L; Zhang W
    J Neurol; 2022 Aug; 269(8):4229-4240. PubMed ID: 35243555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder.
    Lin J; Li X; Xue B; Tong Q; Chen Z; Zhu W; Li J; Xia J
    J Neuroimmunol; 2018 Apr; 317():1-4. PubMed ID: 29501080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
    Claverie R; Perriguey M; Rico A; Boutiere C; Demortiere S; Durozard P; Hilezian F; Dubrou C; Vely F; Pelletier J; Audoin B; Maarouf A
    Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37604695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.
    Gomez-Figueroa E; Noriega-Morales G; Casallas-Vanegas A; Zabala-Angeles I; Garcia-Estrada C; Neri D; Sarachaga AJ; Rivas-Alonso V; Corona-Vazquez T; Flores-Rivera J
    Clin Neurol Neurosurg; 2020 Sep; 196():106007. PubMed ID: 32559706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.
    Zhang L; Tian J; Dong X; Jia Z; Sun Y; Guo L; Tan G; Li B
    Neurol Sci; 2022 Apr; 43(4):2651-2658. PubMed ID: 34585292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
    Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
    Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2 grams versus 1 gram rituximab as maintenance schedule in multiple sclerosis, neuromyelitis optica spectrum disorders and related diseases: What B-cell repopulation data tell us.
    Rual C; Biotti D; Lepine Z; Delourme A; Berre JL; Treiner E; Ciron J
    Mult Scler Relat Disord; 2023 Mar; 71():104563. PubMed ID: 36791624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
    Wang H; Zhou J; Li Y; Wei L; Xu X; Zhang J; Yang K; Wei S; Zhang W
    Ther Adv Neurol Disord; 2021; 14():17562864211056710. PubMed ID: 34950240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
    Yin Z; Qiu Y; Duan A; Fang T; Chen Z; Wu J; Wang Z; Chen G
    J Neurol; 2023 Jun; 270(6):2950-2963. PubMed ID: 36884069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.